|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATION |
|
|
|
|
|
|
The OAB Clinical Care Pathway Mobile APP
|
|
Stephen R. Kraus, MD, MBA, FACS
|
| In this informational video presentation, Stephen Kraus provides an update on the SUFU Overactive Bladder (OAB) Clinical Care Pathway as a dissemination effort to broadcast the advantages of the pathway for both physicians and patients.
|
|
|
|
|
|
|
|
|
|
|
|
| Update on the SUFU OAB Clinical Pathway |
| Stephen Kraus, MD, MBA, FACS |
| An OAB CCP website has been developed as part of the SUFU website. It includes first-line therapy modules including patient education material on conservative behavioral therapies, particularly helpful for providers who do not have this resource. Also, it includes a patient medication tool which will hopefully improve adherence and provide assistance in handling side effects. A smartphone app that digitalizes the roadmap has been developed. This APP is interactive. Part of the dissemination campaign includes partnering with UroToday to create an OAB Center of Excellence. Future plans include the development of a patient registry. |
|
|
|
|
|
| Vaginal Lasers Should Be Part of Every Female Pelvic Medicine and Reconstructive Surgery Practice
|
| Nirit Rosenblum, MD
|
| Nirit Rosenblum discusses vaginal laser therapy detailing the three main types of vaginal laser: Functionated CO2, Radiofrequency, and Er:YAG. Dr. Rosenblum noted that vaginal laser therapy has been looked at as a treatment for recurrent UTIs in women. It appears that overall evidence for vaginal laser therapy is not yet there, as there are no randomized controlled trials for GSM therapy, no long-term studies, and none that compare laser therapy to transvaginal estrogen treatment.
|
|
|
|
|
|
| Disparity in Female Pelvic Examination in the Evaluation of Lower Urinary Tract Symptoms
|
| Aryana Sharrak, Marcus Jamil, MD, Mahdi Bazzi, MD, Ryan Timar, Natalija Kovacevic, MD, Humphrey Atiemo, MD
|
| The primary objective of this study was to investigate the disparity of pelvic and genitourinary exams between male and female patients who present with lower urinary tract symptoms, urinary tract infection, and other urological conditions: as well as, assess for predictors of undergoing pelvic examination. This was a retrospective chart review performed for female and male patients from October 2016 to December 2018.
|
|
|
|
|
|
| The Evaluation of a Novel Non-Surgical, Wearable, Neuromodulation System for Use in the Home on Patients With Overactive Bladder |
| Denise Elser, Nel Gerig, Samir Arora, Kavi Rajendran, Breanne Mangione, Jessica Spear, Samuel Young, Tracy Cameron |
| This was a prospective, open-label study evaluating a non-surgical wearable neuromodulation therapy system with objective feedback of nerve activation. The study was conducted to assess the therapy’s tolerability, usability, and satisfaction. This therapy is a custom-fitted garment embedded with electrodes, used transcutaneously to stimulate the tibial nerve and record electromyography (EMG) signals from the sole of the foot. |
|
|
|
|
|
| Identifying Patient-Centered Research Priorities in Overactive Bladder by Crowdsourcing |
| Aidan Kennedy, Riley Kennedy, Olga Goloubeva, Phillippe Zimmern, Rena Malik |
| The aim of this study was to use Amazon MTurk to identify research topics prioritized by patients with overactive bladder (OAB). Amazon MTurk is a crowdsourcing platform. Users were invited to complete a survey on OAB Research. The Overactive Bladder Awareness Tool – 3 item (OABV3) was used to screen participants. Those that scored 4 or greater took a research prioritization survey. |
|
|
|
|
|
| Barriers to Completion of a Voiding Diary in Patients With Overactive Bladder
|
| Alice Drain, MD; Nirit Rosenblum, MD; Victor Nitti, MD; Benjamin Brucker, MD
|
| The primary aim of this study was to report the percent of patients completing a voiding diary. A secondary aim was to assess what factors may predict diary completion. This was a prospective cohort study of 93 patients undergoing workup for overactive bladder (OAB).
|
|
|
|
|
|
| Outcomes of a Single Trigone-Only vs. 20 Trigone-Sparing Injections of OnabotulinumtoxinA for Refractory Overactive Bladder (OAB) - Beyond the Abstract
|
| Eboo Versi, MD, Ph.D.
|
| It is my hypothesis that the trigone, and only the trigone, should be the site of botulinum toxin A (BTA) injection for the treatment of refractory OAB, and the results of this case series reinforce this view. Given that the vast majority of patients receiving OAB treatment are women, injecting the trigone should be much easier by the vaginal route. In this transvaginal trigone treatment (T3), the injection site would be through the anterior vaginal wall just 5cm proximal to the vaginal introitus and therefore easily accessible in an office setting. As the volume of the trigone is only about 3 cubic cm, a single injection to a 5mm depth should suffice.
|
|
|
|
|
|
|
|
|
|
|
